全球及中国患者服务类App创新趋势及发展动向分析报告2025~2031年 【全新修订】：2025年7月 【出版机构】：中智信投研究网 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 1 患者服务类App市场概述 1.1 产品定义及统计范围 1.2 按照不同产品类型，患者服务类App主要可以分为如下几个类别 1.2.1 不同产品类型患者服务类App增长趋势2020 VS 2024 VS 2031 1.2.2 基础就医服务 1.2.3 健康监测与提醒 1.2.4 远程医疗 1.2.5 其他 1.3 从不同应用，患者服务类App主要包括如下几个方面 1.4 行业发展现状分析 1.4.1 十五五期间患者服务类App行业发展总体概况 1.4.2 患者服务类App行业发展主要特点 1.4.3 进入行业壁垒 1.4.4 发展趋势及建议 2 行业发展现状及"十五五"前景预测 2.1 全球患者服务类App行业规模及预测分析 2.1.1 全球市场患者服务类App总体规模（2020-2031） 2.1.2 中国市场患者服务类App总体规模（2020- ...

Core Insights - Outcomes4Me, a medical technology company based in Massachusetts, raised $21 million in funding in May 2025, led by Salica Investments, with participation from Labcorp Venture Fund and Forecast Labs [1] - The total funding raised by Outcomes4Me to date amounts to $38 million (approximately 270 million yuan), which will be used to further develop its AI-driven cancer care platform aimed at providing personalized and intelligent solutions for patients [1] Funding History - Outcomes4Me has undergone several funding rounds: - Seed Round in November 2020: $4.7 million from Asset Management Ventures [2] - Series A in April 2021: $12 million from Northpond Ventures [2] - Series A+ in May 2025: $21 million from Salica Investments [2] Market Demand and Challenges - The global cancer incidence is rising, with 19.976 million new cases and 9.744 million deaths reported in 2022, leading to increased demand for cancer care [3] - Current challenges in cancer care include low patient treatment adherence, limited access to clinical trial information, and fragmented data across multiple platforms, which affects treatment continuity [3] AI Cancer Care Platform Features - Outcomes4Me's AI cancer care platform includes three core functionalities: - Personalized treatment recommendations using AI and machine learning to analyze patient medical records [4] - Clinical trial matching to improve patient participation rates by integrating data from over 700 medical institutions [4] - Symptom tracking through an app that allows patients to record symptoms and share data with healthcare teams, ensuring data security in compliance with U.S. medical privacy regulations [4] Competitive Landscape - Similar AI-driven cancer care products include PathAI's AI Sight imaging management system and Owkin's MSIntuit CRC digital pathology solution, which aim to enhance patient understanding and treatment optimization [5] Industry Trends in China - China's cancer incidence is also on the rise, with 4.8247 million new cases reported in 2022, accounting for 24.1% of global cases [6] - The Chinese government is promoting AI applications in healthcare, with guidelines released in November 2024 outlining 13 major categories and 84 subcategories for AI technology in the medical field [6] - Several AI-driven cancer care platforms have emerged in China, such as CSCO AI and Ant Group's AI health manager, indicating rapid development in this sector [6] Future Outlook - Hospitals are increasingly adopting "AI + nursing" technologies, with initiatives like the integrated "symptom assessment-AI matching-VR intervention" terminal launched by Sun Yat-sen University Cancer Center [7] - The demand for continuous information and support for cancer patients post-discharge is critical, suggesting a growing need for AI-integrated solutions in cancer care [7]